利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.019 seconds)

    Animal model
    3.
    发明申请
    Animal model 审中-公开

    公开(公告)号：US20040166061A1

    公开(公告)日：2004-08-26

    申请号：US10806782

    申请日：2004-03-23

    Applicant: Biovitrum AB, a Swedish corporation

    Inventor： Sven Enerback ,  Peter Carlsson

    IPC: A61K049/00 ,  C12Q001/68

    CPC classification number: A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0306 ,  A01K2267/0362 ,  A61K38/00 ,  A61K48/00 ,  C07K14/435 ,  C07K14/4702 ,  C07K14/5759 ,  C12N15/8509

    Abstract: According to the invention, a major role for the winged helix protein FKHL14/FOXC2 in regulating energy balance and adiposity is demonstrated. The invention relates to transgenic non-human mammalian animals being capable of expressing the human FKHL14/FOXC2 gene in its adipose tissue. The invention also relates to methods for identifying compounds useful for the treatment of medical conditions related to obesity or diabetes, said compounds being capable of stimulating expression of the human FKHL14/FOXC2 gene, or being capable of stimulating the biological activity of a polypeptide encoded by the human FKHL14/FOXC2 gene. The invention further relates to methods for identifying compounds useful for the treatment of medical conditions related to malnutrition, said compounds being capable of decreasing expression of the human FKHL14/FOXC2 gene, or being capable of decreasing the biological activity of a polypeptide encoded by the human FKHL14/FOXC2 gene.

    Promoter sequences
    4.
    发明申请
    Promoter sequences 审中-公开
    启动子序列

    公开(公告)号：US20050244842A1

    公开(公告)日：2005-11-03

    申请号：US10971560

    申请日：2004-10-22

    Applicant: Sven Enerback ,  Katarina Krook ,  Lena Rondahl ,  Wyeth Wasserman

    Inventor： Sven Enerback ,  Katarina Krook ,  Lena Rondahl ,  Wyeth Wasserman

    IPC: C12N15/85 ,  C12Q1/68 ,  C07H21/04 ,  C12N9/22 ,  C12N15/09 ,  C12P21/06

    CPC classification number: C12N15/85 ,  C12N2830/00 ,  C12N2830/85 ,  C12Q1/6897 ,  G01N2500/00

    Abstract: The present invention relates an isolated promoter region of the mammalian transcription factor FOXC2. The invention also relates to screening methods for agents modulating the expression of FOXC2 and thereby being potentially useful for the treatment of medical conditions related to obesity. The invention further relates to a previously unknown variant of the human FOXC2 gene, derived via the use of an alternative promoter, which produces an additional exon that generates a distinct open reading frame via splicing. The alternative gene encodes a variant of the FOXC2 transcription factor, which is lacking a part of the DNA-binding domain and consequently has a potential regulatory function.

    Abstract translation: 本发明涉及哺乳动物转录因子FOXC2的分离的启动子区域。 本发明还涉及调节FOXC2表达的试剂的筛选方法，因此可用于治疗与肥胖有关的医学病症。 本发明还涉及通过使用替代启动子衍生的人类FOXC2基因的先前未知变体，其产生通过拼接产生不同开放阅读框的另外的外显子。 替代基因编码FOXC2转录因子的变体，其缺乏DNA结合结构域的一部分，因此具有潜在的调节功能。

    Novel response element
    6.
    发明申请
    Novel response element 审中-公开
    新颖的回应元素

    公开(公告)号：US20030143583A1

    公开(公告)日：2003-07-31

    申请号：US10261517

    申请日：2002-10-01

    Applicant: Biovitrum AB, a Swedish corporation

    Inventor： Isabel Climent-Johansson ,  Karin Dahlman-Wright ,  Staffan Lake ,  Wyeth Wasserman

    IPC: C12Q001/68 ,  G06F019/00 ,  G01N033/48 ,  G01N033/50 ,  C07H021/04 ,  C12N009/22 ,  C12P021/02 ,  C12N005/06

    CPC classification number: C12N15/11 ,  C07K14/4701 ,  C07K14/4702 ,  C07K2319/00 ,  C12N15/85 ,  C12N2830/002

    Abstract: The present invention is directed to a novel Afx response element comprising the nucleotide sequence AACATGTT, said nucleotide sequence having a DNA binding site for the human fork head transkription factor Afx. The invention also relates to the use of the Afx response element in the screening for genes as diabetes drug targets and in the bioinformatic analysis of the human genome, said genes in turn being useful in other screening methods for compounds modifying the insulin receptor signaling pathway. A further aspect of the invention is a vector construct comprising the novel nucleotide sequence, a host cell transformed with said vector construct as well as the fusion protein expressed by said host cell.

    Abstract translation: 本发明涉及包含核苷酸序列AACATGTT的新型Afx应答元件，所述核苷酸序列具有人叉头转录因子Afx的DNA结合位点。 本发明还涉及Afx应答元件在筛选基因作为糖尿病药物靶标和在人类基因组的生物信息学分析中的用途，所述基因又可用于修饰胰岛素受体信号通路的化合物的其它筛选方法。 本发明的另一方面是载体构建体，其包含新的核苷酸序列，用所述载体构建体转化的宿主细胞以及由所述宿主细胞表达的融合蛋白。

Patent Agency Ranking